These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder. Papakostas GI, Petersen T, Denninger JW, Montoya HD, Nierenberg AA, Alpert JE, Fava M. Ann Clin Psychiatry; 2003; 15(3-4):187-92. PubMed ID: 14971864 [Abstract] [Full Text] [Related]
28. Plasma catecholamine levels after fluoxetine treatment in depressive patients. Blardi P, de Lalla A, Auteri A, Iapichino S, Dell'Erba A, Castrogiovanni P. Neuropsychobiology; 2005; 51(2):72-6. PubMed ID: 15741747 [Abstract] [Full Text] [Related]
29. Pharmacokinetics of fluoxetine in elderly men and women. Ferguson JM, Hill H. Gerontology; 2006; 52(1):45-50. PubMed ID: 16439824 [Abstract] [Full Text] [Related]
30. Initial Steps to inform selection of continuation cognitive therapy or fluoxetine for higher risk responders to cognitive therapy for recurrent major depressive disorder. Vittengl JR, Anna Clark L, Thase ME, Jarrett RB. Psychiatry Res; 2017 Jul; 253():174-181. PubMed ID: 28388454 [Abstract] [Full Text] [Related]
31. Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. Norman TR, Gupta RK, Burrows GD, Parker G, Judd FK. Int Clin Psychopharmacol; 1993 Jul; 8(1):25-9. PubMed ID: 8473717 [Abstract] [Full Text] [Related]